Also mentions MYCN:
Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531.
x hide permanently

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

ncbi.nlm.nih.gov

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

Nat Commun. 2017 Sep 18;8(1):569

Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

Mentions: MYCN